仿制药-话题@MedSci

#仿制药#

261篇内容 | 5539人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261374, encodeId=f03312613e4f6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=一致性评价通过了，仿制药企的”掘金时代”能到来吗？, objectType=article, longId=125155, objectId=dbf312515595, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbf312515595, replyNumber=0, likeNumber=69, createdTime=2018-01-01, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbf312515595, moduleTitle=一致性评价通过了，仿制药企的”掘金时代”能到来吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbf312515595)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261373, encodeId=a51c12613e35d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=CFDA重磅消息：第一批通过仿制药一致性评价品种公布！, objectType=article, longId=125086, objectId=c15e1250866d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c15e1250866d, replyNumber=0, likeNumber=49, createdTime=2017-12-31, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c15e1250866d, moduleTitle=CFDA重磅消息：第一批通过仿制药一致性评价品种公布！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c15e1250866d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261372, encodeId=8ff812613e288, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准Ixifi（英夫利昔单抗-qbtx），一种类似于Remicade的生物仿制药, objectType=article, longId=123813, objectId=a45b12381316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a45b12381316, replyNumber=0, likeNumber=55, createdTime=2017-12-19, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a45b12381316, moduleTitle=FDA批准Ixifi（英夫利昔单抗-qbtx），一种类似于Remicade的生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a45b12381316)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261371, encodeId=cb9b12613e1c1, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=美国批准Herceptin生物仿制药, objectType=article, longId=122314, objectId=33e712231494, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e712231494, replyNumber=0, likeNumber=65, createdTime=2017-12-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e712231494, moduleTitle=美国批准Herceptin生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e712231494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261370, encodeId=f7ab12613e08f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Celltrion选用Oracle健康科学安全解决方案帮助成本效益型救命药物和生物仿制药上市, objectType=article, longId=115673, objectId=61a61156e380, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61a61156e380, replyNumber=0, likeNumber=68, createdTime=2017-10-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61a61156e380, moduleTitle=Celltrion选用Oracle健康科学安全解决方案帮助成本效益型救命药物和生物仿制药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61a61156e380)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261369, encodeId=7dbf1261369ad, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=《关于仿制药质量和疗效一致性评价工作有关事项的公告》解读, objectType=article, longId=113586, objectId=65671135867a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65671135867a, replyNumber=0, likeNumber=58, createdTime=2017-09-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65671135867a, moduleTitle=《关于仿制药质量和疗效一致性评价工作有关事项的公告》解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65671135867a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261368, encodeId=7c6f126136883, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=《关于仿制药质量和疗效一致性评价工作有关事项的公告》政策解读, objectType=article, longId=113584, objectId=0f26113584e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f26113584e7, replyNumber=0, likeNumber=55, createdTime=2017-09-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f26113584e7, moduleTitle=《关于仿制药质量和疗效一致性评价工作有关事项的公告》政策解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f26113584e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261367, encodeId=1301126136ecc, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=解读关于仿制药质量和疗效一致性评价公告, objectType=article, longId=113554, objectId=72c111355422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72c111355422, replyNumber=0, likeNumber=70, createdTime=2017-09-22, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72c111355422, moduleTitle=解读关于仿制药质量和疗效一致性评价公告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72c111355422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261366, encodeId=ae4512613660f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药一致性评价即将展开, objectType=article, longId=111928, objectId=ce0d111928e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce0d111928e8, replyNumber=0, likeNumber=68, createdTime=2017-09-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce0d111928e8, moduleTitle=仿制药一致性评价即将展开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce0d111928e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261365, encodeId=8cee1261365a4, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA发布48个仿制药开发最终指导原则, objectType=article, longId=108388, objectId=45b01083884b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45b01083884b, replyNumber=0, likeNumber=65, createdTime=2017-08-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45b01083884b, moduleTitle=FDA发布48个仿制药开发最终指导原则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45b01083884b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261364, encodeId=6f8c1261364b5, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Br J Dermatol：治疗银屑病，生物仿制药的ABP 501与阿达木单抗的疗效、安全性、免疫原性相似, objectType=article, longId=107219, objectId=a78110e219d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a78110e219d2, replyNumber=0, likeNumber=60, createdTime=2017-08-01, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a78110e219d2, moduleTitle=Br J Dermatol：治疗银屑病，生物仿制药的ABP 501与阿达木单抗的疗效、安全性、免疫原性相似, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a78110e219d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261363, encodeId=442b126136384, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=外企药品降价进医保目录背后：谈判纯属自愿，提前抵御仿制药, objectType=article, longId=106205, objectId=ed03106205e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed03106205e1, replyNumber=0, likeNumber=55, createdTime=2017-07-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed03106205e1, moduleTitle=外企药品降价进医保目录背后：谈判纯属自愿，提前抵御仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed03106205e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261362, encodeId=5ac5126136209, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=山西推动仿制药一致性评价，解决同药不同效等问题, objectType=article, longId=105070, objectId=d8e11050e0d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8e11050e0d5, replyNumber=0, likeNumber=56, createdTime=2017-07-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8e11050e0d5, moduleTitle=山西推动仿制药一致性评价，解决同药不同效等问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8e11050e0d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261361, encodeId=e24b126136113, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=畅销艾滋病药Truvada仿制药获FDA批准上市, objectType=article, longId=102016, objectId=fb9f10201611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb9f10201611, replyNumber=0, likeNumber=46, createdTime=2017-06-17, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb9f10201611, moduleTitle=畅销艾滋病药Truvada仿制药获FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb9f10201611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261360, encodeId=38f21261360a6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=总局公开征求仿制药一致性评价受理审查指南及相关单据意见, objectType=article, longId=101449, objectId=24e31014495a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24e31014495a, replyNumber=0, likeNumber=60, createdTime=2017-06-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24e31014495a, moduleTitle=总局公开征求仿制药一致性评价受理审查指南及相关单据意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24e31014495a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261359, encodeId=cb0d1261359d1, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=CFDA仿制药一致性评价有调整！, objectType=article, longId=101439, objectId=b5e1101439cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e1101439cf, replyNumber=0, likeNumber=63, createdTime=2017-06-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e1101439cf, moduleTitle=CFDA仿制药一致性评价有调整！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5e1101439cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261358, encodeId=717312613586f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Ann Rheum Dis：生物仿制药ABP 501与阿达木单抗治疗中重度类风湿关节炎的疗效和安全性比较, objectType=article, longId=101283, objectId=bb5010128393, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb5010128393, replyNumber=0, likeNumber=73, createdTime=2017-06-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb5010128393, moduleTitle=Ann Rheum Dis：生物仿制药ABP 501与阿达木单抗治疗中重度类风湿关节炎的疗效和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb5010128393)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261357, encodeId=8a1c126135edc, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准第一个Strattera仿制药，治疗多动症, objectType=article, longId=100426, objectId=f39f10042628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f39f10042628, replyNumber=0, likeNumber=68, createdTime=2017-06-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f39f10042628, moduleTitle=FDA批准第一个Strattera仿制药，治疗多动症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f39f10042628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261356, encodeId=4c2712613569c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=我国首部《中国仿制药蓝皮书（2016年版）》在京发布, objectType=article, longId=98718, objectId=1d3d98e1803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d3d98e1803, replyNumber=0, likeNumber=64, createdTime=2017-05-16, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d3d98e1803, moduleTitle=我国首部《中国仿制药蓝皮书（2016年版）》在京发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d3d98e1803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261355, encodeId=62fb126135554, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=[药企软文]重磅！美罗华生物仿制药在欧洲获得批准, objectType=article, longId=90445, objectId=632a904456c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632a904456c, replyNumber=0, likeNumber=55, createdTime=2017-03-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632a904456c, moduleTitle=[药企软文]重磅！美罗华生物仿制药在欧洲获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632a904456c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

一致性评价通过了，仿制药企的”掘金时代”能到来吗？

2018-01-01

drwjr (审核中...)

前往app查看评论内容

#仿制药#

CFDA重磅消息：第一批通过仿制药一致性评价品种公布！

2017-12-31

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准Ixifi（英夫利昔单抗-qbtx），一种类似于Remicade的生物仿制药

2017-12-19

drwjr (审核中...)

前往app查看评论内容

#仿制药#

美国批准Herceptin生物仿制药

2017-12-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Celltrion选用Oracle健康科学安全解决方案帮助成本效益型救命药物和生物仿制药上市

2017-10-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

《关于仿制药质量和疗效一致性评价工作有关事项的公告》解读

2017-09-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

《关于仿制药质量和疗效一致性评价工作有关事项的公告》政策解读

2017-09-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

解读关于仿制药质量和疗效一致性评价公告

2017-09-22

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药一致性评价即将展开

2017-09-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA发布48个仿制药开发最终指导原则

2017-08-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Br J Dermatol：治疗银屑病，生物仿制药的ABP 501与阿达木单抗的疗效、安全性、免疫原性相似

2017-08-01

drwjr (审核中...)

前往app查看评论内容

#仿制药#

外企药品降价进医保目录背后：谈判纯属自愿，提前抵御仿制药

2017-07-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

山西推动仿制药一致性评价，解决同药不同效等问题

2017-07-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

畅销艾滋病药Truvada仿制药获FDA批准上市

2017-06-17

drwjr (审核中...)

前往app查看评论内容

#仿制药#

总局公开征求仿制药一致性评价受理审查指南及相关单据意见

2017-06-12

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

CFDA仿制药一致性评价有调整！

2017-06-12

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

Ann Rheum Dis：生物仿制药ABP 501与阿达木单抗治疗中重度类风湿关节炎的疗效和安全性比较

2017-06-11

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

FDA批准第一个Strattera仿制药，治疗多动症

2017-06-03

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

我国首部《中国仿制药蓝皮书（2016年版）》在京发布

2017-05-16

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

[药企软文]重磅！美罗华生物仿制药在欧洲获得批准

2017-03-04

科室
- - 订阅+
  - 更多科室
工具
服务